10/518184

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE DT01 Rec'd PCT/PTC 1 6 DEC 20

Application No.:

Based on PCT/JP03/007741

Filed:

Intl. Filing 18 JUNE 2003

1<sup>st</sup> Inventor:

Tatsuya WATANABE

For:

Preventing/Treating Agent for Bone or Joint Diseases

Atty. Dkt. No.

3057 US0P

**Art Unit:** 

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

## **Information Disclosure Statement**

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated 7/16/9

(847) 383-3372

(847) 383-3391

Respectfully submitted

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449/PTO **Application Number** Based on PCT/JP03/007741 Filing Date Intl Date 18 JUNE 2003 INFORMATION DISCLOSURE First Named Inventor Tatsuya WATANABE STATEMENT BY APPLICANT Art Unit tba (Use as many sheets as necessary) **Examiner Name** tba Attorney Docket Number 3057 US0P Sheet 1

			U. S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-		* * * * * * * * * * * * * * * * * * * *		
		US-				
		US-				
		US-				
		US-		<del></del>		
		US-				
		US-				
		US-				
		US-		···		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				


		FOREI	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
	A1	WO 01/44268 A1	06/21/2001	Sterix Limited		
	A2	WO 99/64013	12/16/1999	Sterix Limited		
	A3	WO 99/52890	10/21/1999	Novartis-Erfindungen		
	A4	WO 01/55411 A2	08/02/2001	Millenium Pharmaceuticals		

The state of the s

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-003)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO  INFORMATION DISCLOSURE			re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
			Application Number	Based on PCT/JP03/007741 Intl Date 18 JUNE 2003		
			Filing Date			
STATEMENT BY APPLICANT		First Named Inventor	Tatsuya WATANABE			
(Use as many sheets as necessary)			Art Unit	tba		
			Examiner Name	tba		
Sheet 2	of	2	Attorney Docket Number	3057 US0P		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>A</b> 5	ANDREW M. HO, et al., "Role of the Mouse ank Gene in Control of Tissue Calcification and Arthritis", Science, (2000), pp. 265-270, Vol. 289, No. 14	
		·	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.